Literature DB >> 17531533

AutoCPAP initiation at home: optimal trial duration and cost-effectiveness.

Adel Bachour1, Jussi T Virkkala, Paula K Maasilta.   

Abstract

BACKGROUND: The duration of automatic computer-controlled continuous positive airway pressure device (autoCPAP) initiation at home varies largely between sleep centers. Our objectives were to evaluate the cost-effectiveness and to find the optimal trial duration.
METHODS: Of the 206 consecutive CPAP-naive patients with obstructive sleep apnea syndrome, who were referred to our hospital, 166 received autoCPAP for a 5-day trial at home.
RESULTS: Of the 166 patients, 89 (15 women) showed a successful 5-day autoCPAP trial (normalized oximetry and mask-on time exceeding 4 h/day for at least 4 days). For the first trial day, 88 (53%) patients had normalized oximetry and a mask-on time exceeding 4 h. A 1-day autoCPAP trial EUR 668 was less cost-effective than a 5-day trial EUR 653, with no differences in values of efficient CPAP pressure or residual apnea-hypopnea index (AHI). The systematic requirement of oximetry monitoring raised the cost considerably from EUR 481 to EUR 668.
CONCLUSIONS: In selected patients with obstructive sleep apnea, the optimal duration for initiating CPAP therapy at home by autoCPAP is 5 days. Although a 1-day trial was sufficient to determine the CPAP pressure requirement, it was not cost-effective and had a high rate of failure.

Entities:  

Mesh:

Year:  2007        PMID: 17531533     DOI: 10.1016/j.sleep.2007.01.010

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  9 in total

1.  The Oxford Sleep Resistance test (OSLER) and the Multiple Unprepared Reaction Time Test (MURT) detect vigilance modifications in sleep apnea patients.

Authors:  Anniina Alakuijala; Paula Maasilta; Adel Bachour
Journal:  J Clin Sleep Med       Date:  2014-10-15       Impact factor: 4.062

2.  Long-term CPAP treatment improves asthma control in patients with asthma and obstructive sleep apnoea.

Authors:  Paula Kauppi; Patrick Bachour; Paula Maasilta; Adel Bachour
Journal:  Sleep Breath       Date:  2016-04-07       Impact factor: 2.816

3.  T1 measurements for detection of expansion of the myocardial extracellular volume in chronic obstructive pulmonary disease.

Authors:  Tomas G Neilan; Jessie P Bakker; Bhavneesh Sharma; Robert L Owens; Hoshang Farhad; Ravi V Shah; Siddique A Abbasi; Puja Kohli; Joel Wilson; Anthony DeMaria; Michael Jerosch-Herold; Raymond Y Kwong; Atul Malhotra
Journal:  Can J Cardiol       Date:  2014-08-19       Impact factor: 5.223

4.  CPAP interface: satisfaction and side effects.

Authors:  Adel Bachour; Pirjo Vitikainen; Paula Virkkula; Paula Maasilta
Journal:  Sleep Breath       Date:  2012-07-05       Impact factor: 2.816

5.  Agreement between 95th percentile pressure based on a 7-night auto-adjusting positive airway pressure trial vs. equation-based predictions in sleep apnea.

Authors:  Luis Torre-Bouscoulet; Armando Castorena-Maldonado; Elodia López-Escárcega; Juan Carlos Vázquez-García; Rogelio Pérez-Padilla
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

6.  Willingness score obtained after a short CPAP trial predicts CPAP use at 1 year.

Authors:  Hanna-Riikka Kreivi; Paula Maasilta; Adel Bachour
Journal:  Sleep Breath       Date:  2013-06-28       Impact factor: 2.816

7.  Rates of initial acceptance of PAP masks and outcomes of mask switching.

Authors:  Adel Bachour; Pirjo Vitikainen; Paula Maasilta
Journal:  Sleep Breath       Date:  2015-12-10       Impact factor: 2.816

8.  Oximetry Monitoring Recommended During PAP Initiation for Sleep Apnea in Patients With Obesity or Nocturnal Hypoxemia.

Authors:  Victor Koivumäki; Paula Maasilta; Adel Bachour
Journal:  J Clin Sleep Med       Date:  2018-11-15       Impact factor: 4.062

9.  Positive airway pressure therapy for obstructive sleep apnea in patients with Osteogenesis imperfecta: a prospective pilot study.

Authors:  Heidi Arponen; Adel Bachour; Leif Bäck; Helena Valta; Antti Mäkitie; Outi Mäkitie; Janna Waltimo-Sirén
Journal:  BMC Musculoskelet Disord       Date:  2021-01-11       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.